Sector Update: Health Care Stocks End on Positive Ground
4:07PM ET 6/21/2019 MT NewswiresTop Health Care Stocks JNJ -0.05% PFE +0.87% ABT +0.16% MRK 0.00% AMGN +0.84% Health care stocks closed moderately higher this afternoon, turning...
Quotes Snapshot > VRTX
Vertex Pharmaceuticals Inc VRTX:NASDAQ
Last Price$176.37NASDAQ Closing Price as of 4:15PM ET 7/15/19
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.58(0.33%)
Bid (Size)$151.80 (1)
Ask (Size)$176.37 (1)
Day Low / High$174.70 - 178.08
Volume1.1 M
Read more news Recent News
Sector Update: Health Care
3:55PM ET 6/21/2019 MT NewswiresHealth care stocks were moderately higher this afternoon, turning around their prior declines. At last look, the NYSE Health Care Index was rising almost...
FDA Clears Vertex Pharma's Cymdeko for Cystic Fibrosis Patients Ages 6 Years and Older
2:48PM ET 6/21/2019 MT NewswiresVertex Pharmaceuticals (VRTX) was narrowly higher this afternoon, reversing a nearly 1% decline earlier Friday, after the US Food and Drug Administration...
Sector Update: Biotechs Lift Health Care Stocks to Large Gain
3:55PM ET 6/07/2019 MT NewswiresTop Health Care Stocks JNJ +1.70% PFE +0.80% ABT +1.07% MRK +1.38% AMGN +0.67% Health care stocks were ending near their session highs, with the NYSE...
View all Commentary and Analysis
Vertex Pharmaceuticals: A Stock That Continues To Impress In 2019
3:05PM ET 7/01/2019 Seeking AlphaVertex Pharmaceuticals Is A Good Long-Term Investment
1:31PM ET 6/26/2019 Seeking AlphaVertex Makes Strong Push Into Crispr Tech With 2 Deals At Once
4:31PM ET 6/17/2019 Seeking AlphaBIIB Is For Buy-O-Gen
10:30AM ET 6/12/2019 Seeking AlphaCompany Profile
Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
| Address | 50 Northern Avenue Boston, Massachusetts 02210 |
| Phone | +1.617.341.6100 |
| Number of Employees | 2,500 |
| Recent SEC Filing | 07/15/2019 4 |
| Chairman, President & Chief Executive Officer | Jeffrey M. Leiden |
| Chief Financial Officer & Executive Vice President | Charles F. Wagner |
| Chief Scientific Officer & EVP-Global Research | David Matthew Altshuler |
| Chief Medical Officer & Executive Vice President | Reshma Kewalramani |
Company Highlights
| Price Open | $176.16 |
| Previous Close | $175.79 |
| 52 Week Range | $151.80 - 195.81 |
| Market Capitalization | $45.2 B |
| Shares Outstanding | 256.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 07/24/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 21.18 |
| Earnings per Share | $8.37 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.0 B |
| Net Profit Margin | 66.24% |
| Return on Equity | 58.43% |
Analyst Ratings as of 07/05/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |